Literature DB >> 33984147

Neurocognitive functions in primary CNS lymphoma.

Denise D Correa1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33984147      PMCID： PMC8328027          DOI： 10.1093/neuonc/noab113

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.

Authors:  Michael Linnebank; Susanna Moskau; Annika Jürgens; Matthias Simon; Alexander Semmler; Katjana Orlopp; Axel Glasmacher; Christopher Bangard; Marlies Vogt-Schaden; Horst Urbach; Ingo G H Schmidt-Wolf; Hendrik Pels; Uwe Schlegel
Journal:  Neuro Oncol       Date:  2008-09-19       Impact factor: 12.300

2.  Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.

Authors:  Christian Grommes; James L Rubenstein; Lisa M DeAngelis; Andres J M Ferreri; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

3.  Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.

Authors:  Nancy D Doolittle; Agnieszka Korfel; Meredith A Lubow; Elisabeth Schorb; Uwe Schlegel; Sabine Rogowski; Rongwei Fu; Edit Dósa; Gerald Illerhaus; Dale F Kraemer; Leslie L Muldoon; Pasquale Calabrese; Nancy Hedrick; Rose Marie Tyson; Kristoph Jahnke; Leeza M Maron; Robert W Butler; Edward A Neuwelt
Journal:  Neurology       Date:  2013-05-17       Impact factor: 9.910

4.  Delayed neurotoxicity in primary central nervous system lymphoma.

Authors:  Antonio M P Omuro; Leah S Ben-Porat; Katherine S Panageas; Amy K Kim; Denise D Correa; Joachim Yahalom; Lisa M Deangelis; Lauren E Abrey
Journal:  Arch Neurol       Date:  2005-10

5.  Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Authors:  Caroline Houillier; Luc Taillandier; Sylvain Dureau; Thierry Lamy; Mouna Laadhari; Olivier Chinot; Cecile Moluçon-Chabrot; Pierre Soubeyran; Remy Gressin; Sylvain Choquet; Gandhi Damaj; Antoine Thyss; Julie Abraham; Vincent Delwail; Emmanuel Gyan; Laurence Sanhes; Jérôme Cornillon; Reda Garidi; Alain Delmer; Marie-Laure Tanguy; Ahmad Al Jijakli; Pierre Morel; Pascal Bourquard; Marie-Pierre Moles; Adrien Chauchet; Thomas Gastinne; Jean-Marc Constans; Adriana Langer; Antoine Martin; Patricia Moisson; Lucette Lacomblez; Nadine Martin-Duverneuil; Daniel Delgadillo; Isabelle Turbiez; Loïc Feuvret; Nathalie Cassoux; Valérie Touitou; Damien Ricard; Khê Hoang-Xuan; Carole Soussain
Journal:  J Clin Oncol       Date:  2019-02-20       Impact factor: 44.544

6.  Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.

Authors:  Denise D Correa; Erica Braun; Maria Kryza-Lacombe; Ka-Wai Ho; Anne S Reiner; Katherine S Panageas; Joachim Yahalom; Craig S Sauter; Lauren E Abrey; Lisa M DeAngelis; Antonio Omuro
Journal:  J Neurooncol       Date:  2019-08-03       Impact factor: 4.130

Review 7.  Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.

Authors:  D D Correa; L Maron; H Harder; M Klein; C L Armstrong; P Calabrese; J E C Bromberg; L E Abrey; T T Batchelor; D Schiff
Journal:  Ann Oncol       Date:  2007-02-06       Impact factor: 32.976

8.  Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

Authors:  Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Christopher P Fox; Elisabeth Schorb; Paul La Rosée; Mascha Binder; Alberto Fabbri; Valter Torri; Eleonora Minacapelli; Monica Falautano; Fiorella Ilariucci; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Peter Johnson; Kim M Linton; Tobias Pukrop; Jette Sønderskov Gørløv; Monica Balzarotti; Georg Hess; Ulrich Keller; Stephan Stilgenbauer; Jens Panse; Alessandra Tucci; Lorella Orsucci; Francesco Pisani; Alessandro Levis; Stefan W Krause; Hans J Schmoll; Bernd Hertenstein; Mathias Rummel; Jeffery Smith; Michael Pfreundschuh; Giuseppina Cabras; Francesco Angrilli; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Jürgen Finke; Michele Reni; Franco Cavalli; Emanuele Zucca; Gerald Illerhaus
Journal:  Lancet Haematol       Date:  2017-10-17       Impact factor: 18.959

9.  Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review.

Authors:  Matthijs van der Meulen; Linda Dirven; Esther J J Habets; Martin J van den Bent; Martin J B Taphoorn; Jacoline E C Bromberg
Journal:  Lancet Oncol       Date:  2018-08       Impact factor: 41.316

10.  Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.

Authors:  Matthijs van der Meulen; Linda Dirven; Esther J J Habets; Katerina Bakunina; Marion Smits; Hakim C Achterberg; Tatjana Seute; Gavin Cull; Harry Schouten; Josée M Zijlstra; Dieta Brandsma; Roelien H Enting; Max Beijert; Martin J B Taphoorn; Martin J van den Bent; Samar Issa; Jeanette K Doorduijn; Jacoline E C Bromberg
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.